Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Prognostic biomarkers in malignant lymphomas.

Randy D Gascoyne¹, Andreas Rosenwald, Sibrand Poppema

¹British Columbia Cancer Agency, Department of Pathology and Experimental Therapeutics, Vancouver, BC, Canada. rgascoyn@bccancer.bc.ca

Leukemia & Lymphoma

|July 28, 2010

Summary

Recent research identifies biomarkers for malignant lymphoma subtypes, aiding prognosis. Studies explore molecular features and immune interactions for novel therapeutic targets in clinical practice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma.

Cell death discovery·2022

Same author

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.

HemaSphere·2022

Same author

MYC multimers shield stalled replication forks from RNA polymerase.

Nature·2022

Same author

Panel Sequencing of Primary Cutaneous B-Cell Lymphoma.

Cancers·2022

Same author

Vitamin D Receptor Expression Is Significantly Decreased in Bone Metastases Compared to Matched Primary Breast Cancer Tumours.

Cancer investigation·2022

Same author

Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.

Cancers·2022

Area of Science:

Oncology
Hematology
Immunology

Background:

Malignant lymphomas comprise diverse subtypes with distinct molecular characteristics and clinical behaviors.
Understanding the tumor microenvironment and immune cell interactions is crucial for disease progression.
Identifying prognostic biomarkers is essential for improving patient outcomes in lymphoma.

Purpose of the Study:

To review recent advances in translational and clinical research on biomarkers for malignant lymphomas.
To highlight the identification of novel therapeutic targets through biomarker and signaling pathway research.
To discuss the translation of research findings into routine clinical practice.

Main Methods:

Review of genomic, genetic, and molecular studies on lymphoma subtypes.

Related Experiment Videos

Last Updated: Jun 10, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Analysis of research on cytokine and chemokine networks in Hodgkin lymphoma.

Evaluation of efforts to develop widely applicable techniques for biomarker research.

Main Results:

Identification of distinct molecular subgroups within diffuse large B-cell lymphomas.
Elucidation of complex interactions between follicular lymphoma cells and the immune microenvironment.
Understanding the role of inflammatory cells in creating a tumor-permissive environment.

Conclusions:

Biomarker research in malignant lymphomas offers potential for novel therapeutic strategies.
Translational research is key to applying molecular findings to clinical practice.
Continued investigation into biomarkers will improve lymphoma patient prognosis.